Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
HAUPPAUGE, N.Y. - Minicarm.com announced Monday it has secured an allocation of Hologic’s Fluoroscan Insight FD Mini C-Arm systems for resale in the United States as Hologic winds down commercial activities for this product line.
The imaging solutions provider will offer sales support for the remaining inventory, providing U.S. customers continued access to the compact fluoroscopic imaging system used in orthopedic and extremity procedures.
"We are thrilled to work closely with Hologic to make sure their Fluoroscan Insight FD systems are available to US customers at this pivotal time," said Joshua Bacon, VP at Minicarm.com.
Under the distribution arrangement, Minicarm.com will provide direct sales, marketing and customer support across the U.S., along with training and education for medical staff.
The company will target customers looking to upgrade from older Hologic Fluoroscan models. Minicarm.com was founded by Christopher Bacon, who was also the technical founder of Orthoscan.
Hologic (NASDAQ:HOLX) is a medical technology company primarily focused on women’s health through early detection and treatment solutions. With a market capitalization of $14.77 billion and annual revenue of $4.04 billion, the company maintains strong financial health, earning a "GREAT" rating from InvestingPro analysts.
The announcement comes as Hologic transitions away from commercial activities related to the Fluoroscan Insight product line, according to the company’s press release statement. According to InvestingPro data, Hologic operates with a moderate debt level and maintains strong liquidity, with current assets significantly exceeding short-term obligations. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, covering this and 1,400+ other top US stocks.
In other recent news, Hologic Inc. reported its fiscal third-quarter 2025 earnings, surpassing Wall Street expectations with an earnings per share (EPS) of $1.08, compared to the forecast of $1.05. The company’s revenue reached $1.024 billion, exceeding the anticipated $1.01 billion, driven by strong performance in the Skeletal Health and GYN-Surgical segments. Mizuho responded to these results by raising its price target for Hologic to $75.00 from $70.00, while maintaining an Outperform rating. RBC Capital also upgraded Hologic’s stock to Outperform, raising its price target to $87.00, citing expected fiscal year 2026 organic revenue growth guidance exceeding current estimates. Meanwhile, BTIG reiterated its Neutral rating on Hologic, highlighting the company’s stronger-than-expected quarterly performance. Additionally, Blackstone Inc. and TPG Inc. have reportedly renewed their interest in acquiring Hologic, re-engaging with the company’s board for a potential takeover. This follows a previous offer exceeding $16 billion that was rejected earlier this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.